In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla

被引:75
作者
Caruthers, SD
Neubauer, AM
Hockett, FD
Lamerichs, R
Winter, PM
Scott, MJ
Gaffney, PJ
Wickline, SA
Lanza, GM
机构
[1] Washington Univ, Sch Med, Div Cardiol, St Louis, MO 63110 USA
[2] Philips Med Syst, Andover, MA USA
[3] Washington Univ, Dept Biomed Engn, St Louis, MO USA
[4] Philips Res Labs, Eindhoven, Netherlands
[5] St Thomas Hosp, Dept Surg, London SE1 7EH, England
关键词
MRI; spectroscopy; fluorine; fibrin; nanoparticles; molecular imaging; in vitro;
D O I
10.1097/01.rli.0000199281.60135.6a
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives: This study explored the use of F-19 spectroscopy and imaging with targeted perfluorocarbon nanoparticles for the simultaneous identification of multiple biosignatures at 1.5 T. Materials and Methods: Two nanoparticle emulsions with perfluoro-15-crown-5-ether (CE) or perfluorooctylbromide (PFOB) cores were targeted in vitro to fibrin clot phantoms (n = 12) in 4 progressive ratios using biotin avidin interactions. The CE nanoparticles incorporated gadolinium. Fluorine images were acquired using steady-state gradient-echo techniques; spectra using volume-selective and nonselective sampling. Results: On conventional T1-weighted imaging, clots with CE nanoparticles enhanced as expected, with intensity decreasing monotonically with CE concentration. All clots were visualized using wide bandwidth fluorine imaging, while restricted bandwidth excitation permitted independent imaging of CE or PFOB nanoparticles. Furthermore, F-19 imaging and spectroscopy allowed visual and quantitative confirmation of relative perfluorocarbon nanoparticle distributions. Conclusions: F-19 MRI/S molecular imaging of perfluorocarbon nanoparticles in vitro suggests that noninvasive phenotypic characterization of pathologic biosignatures is feasible at clinical field strengths.
引用
收藏
页码:305 / 312
页数:8
相关论文
共 48 条
[1]  
Anderson SA, 2000, MAGNET RESON MED, V44, P433, DOI 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO
[2]  
2-9
[3]   PERFLUOROOCTYLBROMIDE AS A CONTRAST AGENT FOR CT AND SONOGRAPHY - PRELIMINARY CLINICAL-RESULTS [J].
BEHAN, M ;
OCONNELL, D ;
MATTREY, RF ;
CARNEY, DN .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1993, 160 (02) :399-405
[4]  
Edgell T, 1996, THROMB HAEMOSTASIS, V75, P595
[5]   Effect of carbogen on tumor oxygenation: Combined fluorine-19 and proton MRI measurements [J].
Fan, XB ;
River, JN ;
Zamora, M ;
Al-Hallaq, HA ;
Karczmar, GS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04) :1202-1209
[6]   Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques [J].
Flacke, S ;
Fischer, S ;
Scott, MJ ;
Fuhrhop, RJ ;
Allen, JS ;
McLean, M ;
Winter, P ;
Sicard, GA ;
Gaffney, PJ ;
Wickline, SA ;
Lanza, GM .
CIRCULATION, 2001, 104 (11) :1280-1285
[7]   PHARMACOKINETICS AND SIDE-EFFECTS OF PERFLUOROCARBON-BASED BLOOD SUBSTITUTES [J].
FLAIM, SF .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1994, 22 (04) :1043-1054
[8]  
Haake E, 1999, MAGNETIC RESONANCE I
[9]   Liver-specific MR imaging contrast agents [J].
Hahn, PF ;
Saini, S .
RADIOLOGIC CLINICS OF NORTH AMERICA, 1998, 36 (02) :287-+
[10]   Noninvasive detection of clinically occult lymph-node metastases in prostate cancer [J].
Harisinghani, MG ;
Barentsz, J ;
Hahn, PF ;
Deserno, WM ;
Tabatabaei, S ;
van de Kaa, CH ;
de la Rosette, J ;
Weissleder, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (25) :2491-U5